PMID- 38415046
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240229
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 15
DP  - 2024
TI  - Real-world safety and effectiveness of secukinumab in adult patients with 
      moderate to severe plaque psoriasis: results from postmarketing surveillance in 
      Korea.
PG  - 20406223241230180
LID - 10.1177/20406223241230180 [doi]
LID - 20406223241230180
AB  - BACKGROUND: Secukinumab, a fully human monoclonal antibody, was approved in Korea 
      for the treatment of moderate to severe psoriasis in September 2015. OBJECTIVES: 
      To assess the safety and effectiveness of secukinumab in patients with moderate 
      to severe psoriasis in Korea. DESIGN: Multicenter, real-world, noninterventional 
      study conducted over 6 years. METHODS: Adults with moderate to severe psoriasis 
      were enrolled. Safety was assessed by evaluating adverse events (AEs), 
      treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using 
      the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage 
      of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24. RESULTS: 
      Overall, 829 and 542 patients were included in the safety and effectiveness sets, 
      respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 
      4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient 
      years, respectively. The absolute PASI score decreased from 16.1 +/- 7.1 (baseline) 
      to 1.6 +/- 2.4 (week 24), with a similar reduction in biologic-naive (16.4 +/- 7.3 to 
      1.5 +/- 2.2) and biologic-experienced (14.8 +/- 5.9 to 2.4 +/- 3.2) groups. At week 24, 
      PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, 
      PASI 75/90 were higher in biologic-naive (96.6%/65.8%) than biologic-experienced 
      patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 
      28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts. CONCLUSION: 
      Secukinumab showed sustained effectiveness and favorable safety profile in adult 
      patients with moderate to severe psoriasis in Korea.
CI  - (c) The Author(s), 2024.
FAU - Kim, Byung Soo
AU  - Kim BS
AD  - Department of Dermatology, School of Medicine, Pusan National University, Busan, 
      Republic of Korea.
FAU - Kim, Dong Hyun
AU  - Kim DH
AD  - Department of Dermatology, CHA Bundang Medical Center, CHA University School of 
      Medicine, Seongnam, Republic of Korea.
FAU - Shin, Bong Seok
AU  - Shin BS
AD  - Department of Dermatology, Chosun University Hospital, Gwangju, Republic of 
      Korea.
FAU - Lee, Eun-So
AU  - Lee ES
AD  - Department of Dermatology, Ajou University School of Medicine, Suwon, Republic of 
      Korea.
FAU - Jo, Seong Jin
AU  - Jo SJ
AD  - Department of Dermatology, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Bang, Chul Hwan
AU  - Bang CH
AD  - Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul, Republic of Korea.
FAU - Yun, Yeojun
AU  - Yun Y
AUID- ORCID: 0009-0007-4319-588X
AD  - Novartis Korea Ltd, Seoul, Republic of Korea.
FAU - Choe, Yong Beom
AU  - Choe YB
AD  - Department of Dermatology, Konkuk University School of Medicine, Seoul 05030, 
      Republic of Korea.
AD  - Research Institute of Medical Science, Konkuk University School of Medicine, 
      Seoul 05030, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20240226
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC10898308
OTO - NOTNLM
OT  - effectiveness
OT  - psoriasis
OT  - real-world evidence
OT  - safety
OT  - secukinumab
COIS- BSK served as a scientific adviser, a clinical study investigator, and/or a 
      speaker for Abbvie, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, 
      Celltrion, Eli Lilly, Galderma, GlaxoSmithKline, Green Cross, Janssen, Kyowa 
      Hakko Kirin, LEO-Pharma, Novartis, Regeneron, Samsung, Sanofi, and UCB. SJJ 
      reported receiving grants from AbbVie, Boehringer Ingelheim, Bristol Myers 
      Squibb, Celltrion Healthcare, Green Cross Laboratories, Pfizer, and UCB and 
      personal fees from AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals, LEO 
      Pharma, Novartis, and Sanofi. CHB has served as an investigator in clinical 
      trials sponsored by AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, 
      Celltrion, Janssen, Novartis, Pfizer, and UCB biopharma, and has received 
      consultancy fees from AbbVie, Boehringer Ingelheim, Janssen, Kolon Pharma, Lilly, 
      and Novartis, and fees for speaking from AbbVie, Janssen, Lilly, and Novartis. 
      DHK served as a scientific adviser, a clinical study investigator, and/or a 
      speaker for AbbVie, Bristol-Myers Squibb, Celltrion, Eli Lilly, Green Cross, 
      Janssen, LEO-Pharma, Novartis, and UCB. E-SL received grants for clinical 
      research from AbbVie, Inc., Bristol-Myers Squibb, Celgene Corporation, Cell 
      Biotech, Lilly, Janssen Pharmaceuticals, Inc., and Servier; served as an advisor 
      or consultant for AbbVie, Inc., Celgene Corporation, Galderma Korea, Janssen 
      Pharmaceuticals, Inc., Lilly, and Novartis Pharmaceuticals Corporation. YY is an 
      employee of Novartis Korea Ltd. BSS and YBC report no competing interests.
EDAT- 2024/02/28 06:43
MHDA- 2024/02/28 06:44
PMCR- 2024/02/26
CRDT- 2024/02/28 03:56
PHST- 2023/07/14 00:00 [received]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/28 06:44 [medline]
PHST- 2024/02/28 06:43 [pubmed]
PHST- 2024/02/28 03:56 [entrez]
PHST- 2024/02/26 00:00 [pmc-release]
AID - 10.1177_20406223241230180 [pii]
AID - 10.1177/20406223241230180 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2024 Feb 26;15:20406223241230180. doi: 
      10.1177/20406223241230180. eCollection 2024.